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Abstract: Introduction: Serum ferritin was demonstrated to be a useful tool to predict the risk in patients who undergo 
hematopoietic stem cell transplantation (HCT). Still it is not clear if its predictive value solely represents iron overload 
(IO) and published results are sometimes contradictory. So the objective of present study was to determine relationship 
between elevated pre-HCT serum ferritin levels, morbidity and mortality after allogeneic hematopoietic stem cell 
transplantation (allo-HCT) on one side, and its correlations with various risk indexes which were developed recently to 
predict outcomes after allo-HCT on the other side. 
Patients and Methods: In this retrospective study we have reviewed medical records of one hundred six consecutive 
patients (52 males and 54 females), with a median age of 32 years (range, 5 to 60), who underwent allo-HCT with 
unmanipulated grafts between Jan 2013 and Dec2014. We retrieved pre-allo-HCT serum ferritin levels and also 
calculated risk indexes before HCT. The incidence of complications and outcomes after allo-HCT was assessed. The 
median follow-up period was 12 (range, 4-27) months after allo-HCT. 
Results: We have determined a cuttoff ferritin level of 500 ng/mL for early complications and 737 for outcomes. We 
found increased incidence of number of febrile neutropenic episodes (P =0.02), number of bacterial infection episodes (P 
=0.009), pneumonias (P =0.039), slower period of neutrophil engraftment (P=0.032), demand for multiple red blood cell 
(RBC) transfusions (P =0.002) within 100 days post transplantation. A significant association was found between pre-
transplant ferritin concentrations and different risk indexes; European Group for Blood and Marrow Transplantation 
(EBMT) risk score (P=0.001), Hematopoietic cell transplantation comorbidity index (HCT-CI) (P=0.003), Pre-transplant 
Assessment of Mortality (PAM) score (P=0.007) and disease risk (DR) (P =0.037). 
Conclusion: On the one hand we did confirmed that even moderate serum ferritin elevation is associated with increased 
incidence of infections, slower period to engraftment and increasing demand of RBC units transfusions, but strong 
correlation with pre-transplant indexes that take into account disease risk raises the question if IO is the only factor that 
adversely affect the outcome of HCT in patients with increased ferritin. This should be studied in prospective trials. 
Keywords: Hematopoietic stem cell transplantation, Allogeneic, iron overload, Serum ferritin, Early infectious 
complications, Risk indexes. 
INTRODUCTION 
Iron overload is common in patients undergoing 
allogeneic hematopoietic stem cell transplantation 
(HCT). The main causes of IO in HCT are prolonged 
dys-erythropoiesis, increased intestinal iron absorption 
due to anemia and chemo-therapy associated 
mucositis which leads to increased iron absorption, 
transfusion burden and release of iron from injured 
tissues [1]. 
 Many studies have shown an association between 
elevated serum ferritin before HCT (used as a 
surrogate measure of iron overload) and adverse 
outcomes [7-10, 13], mostly from an increase in 
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[7, 8], although some of these studies also suggested 
an association between IO and acute graft versus host 
disease (GvHD) [9, 10] or hepatic veno-occlusive 
disease (VOD) [12]. However, these studies were 
retrospective and mostly based on surrogate measures 
of iron burden, especially serum ferritin. 
 Different cutoffs ferritin was used in several studies, 
e.g., (Altes et al. 2002 (F3000)[23]; Armand et al. 
2007 (F2515) [24]; Kataoka et al. 2009 (F599) [8]; 
Mahindra et al. 2009b (F1910) [9]; Lee et al.2009 
(F1000) [26]; Sucak et al. 2010 (F500) [7], so the 
optimal cutoff ferritin which accurately reflects 
increased risk of complications after HCT is not well 
estimated. 
 In the other hand when pre-transplant IO was 
measured using liver magnetic resonance imaging (R2-
MRI), found contradictory results. There was no 
association between pre-transplant IO defined by R2-
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MRI measured liver iron concentration (LIC) and overall 
survival (OS), NRM, relapse rate, GvHD, bacterial, viral 
or fungal infections [14, 15]. This results doesn’t 
contradict the previous data that used serum ferritin for 
assessment of IO, because these studies had limited 
number of patients included and small studies in HCT 
usually have limited power to demonstrate the impact 
of single factor, like IO, on the outcomes. So ferritin 
level is still accepted as a standard risk assessment 
tool in HCT recipients.  
 Many accepted risk indexes likes; Disease risk 
index(DR), Hematopoietic cell transplantation co-
morbidity index (HCT-CI), European Group for Blood 
and Marrow Transplantation (EBMT) risk score and 
Pre-transplant Assessment of Mortality Score (PAM) 
were developed to predict outcomes and complications 
of allo-HCT[17-20]. Some of them include parameters 
that could be attributed to IO, but there is limited data 
on correlation between these indexes and ferritin 
levels. 
 Summarizing, a substantial number of studies have 
been published on the topic of serum ferritin in HCT, 
but still there are several controversial points. So we 
focused our study on the impact of pre allo-HCT serum 
ferritin on different events post allo-HCT; Early 
infectious complications, mucositis, engraftment, veno-
oclusive disease, GvHD, and on determining the 
optimal cutoff for increased risk of complications and 
mortality. Also we evaluated how a serum ferritin level 
was correlated with the other tools of HCT risk 
assessment, like pre-transplant indexes. 
MATERIALS AND METHODS 
We have retrospectively evaluated a group of one 
hundred and six consecutive patients who underwent 
unmanipulated allo-HCT in R.M. Gorbacheva Memorial 
Institute of Children Oncology, Hematology and 
Transplantation at the St. Petersburg Pavlov State 
Medical University, St. Petersburg, between 
01/01/2013 and 31/12/2014. The inclusion criteria were 
as follows: (1) First allo-HCT from HLA-compatible 
related, unrelated and haplo-identical donors; (2) 
Primary malignant or non-malignant disease; (3) Age: 5 
to 60 years; (4) Karnofsky performance status 70 %. 
 The cohort included 52 men and 54 women with a 
median age at transplantation of 31.8 (range, 5 to 60) 
years. Underlying diseases were acute myeloid 
leukemia (n=78), myelodysplastic syndrome (n= 12), 
primary myelofibrosis (n=3), aplastic anemia (n=11) 
and B-thalassemia major (n=2). Stem cell transplants 
were from HLA-identical siblings (n=26), haplo-identical 
(n=9), or unrelated volunteer donors (n=71). The 
conditioning regimens were myeloablative (MAC) in 26 
patients, and reduced intensity (RIC) in the rest of this 
group. The study was approved by the Institutional 
Review Board at the St.Petersburg State Pavlov 
Medical University. Each patient has given an informed 
consent for the use of personal data. The median 
follow-up period was 12 (range, 4-27) months after allo-
HCT. Baseline characteristics of the patients are given 
in (Table 1). 
 Mucositis was graded on a scale of 0 to 4, 
according to Common Toxicity Criteria, version 4, from 
the National Cancer Institute. The International 
Consensus on opportunistic fungal infections was 
established by the EORTC/MSG [16]. Bacterial 
infection was defined as recovery of a recognized 
pathogen from, at least, 2 blood or urine cultures 
yielding the same organism. For each patient, the 
numbers of bacterial, viral and fungal infections were 
calculated, according to CIBMTR Instructions for 100 
Days post-HCT (Data Form 2100). Document Number: 
A00531 version 1.1 (7/20/2012). Neutrophil recovery 
was defined as an ANC of 500/μL for the first 3 
consecutive days. (DR) index, (HCT-CI), (EBMT) risk 
and (PAM) scores were calculated according to 
Armand et al. [17], Sorror ML et al. [18], A Gratwohl 
[19] and Parimon T et al. [20], respectively. PAM score 
and DR index were calculated only in malignant 
diseases. Acute GvHD was graded according to 
Gratwohl criteria [21]. Graft-vs-host disease - relapse 
free survival (GRFS) was considered according to 
Shernan G. Holtan, et al. [22]. A diagnosis of sinusoidal 
obstruction syndrome (Hepatic veno-occlusive disease) 
was made on the basis of Seattle criteria, as described 
by McDonald et al. [11]. Continuous variables in the 2 
groups were compared by means of the Mann-Whitney 
test. Categorical variables were compared using the 
Chi-square test. GRFS, OS, NRM and event-free 
survival (EFS) were calculated using the Kaplan-Meier 
method. Possible risk factors were tested using the log-
rank test. Relapse was counted as competing risk for 
non-relapse mortality. Cutoff levels of ferritin amounts 
were determined using ROC - analysis. The 
association between serum ferritin levels and different 
risk indexes (DR, EBMT, HC-CI and PAM score) was 
calculated according to Kruskal-Wallis Test. Correlation 
between ferritin and C-reactive protein (CRP) was 
evaluated using Spearman method. The calculations 
were made with SPSS software (version 17).  
Prognosis of Ferritin in Allogeneic-HCT Global Journal of Hematology and Blood Transfusion, 2015, Vol. 2, No. 2    3 
Table 1: Patients Baseline Characteristics 
  % Range 
Total number of patients 106   
 Male 52 49  
 Female 54 51  
 Median age (years) 31.8  (5-60)  
Diagnosis    
 Acute myeloid leukemia 78 73.6  
 Myelodysplastic syndrome  12 11.32  
 Primary myelofibrosis 3 2.8  
 Aplastic anemia 11 10.3  
 B-Thalassemia major 2 1.8  
Status of malignant 
disease (n=93) 
   
 Complete remission 60 64.5  
 Incomplete remission 33 35.5  
Conditioning regimen 
 
   
 MAC 26 24.5  
 RIC 65 75.5  
Source of stem cells 
 
   
 BM 48 45.2  
 PBSC 55 51.8  
 PBSC+BM 3 2.80  
 Stem cell dose CD34+ / *10
6
 4.9  (1.1-14.1) 




12.3  (1.2-39.5) 
Donor     
 M / F 69/37 65/35  
 Median donor age 32.4  (3.9-56) 
Median ferritin level pre-allo-





104  (50-155) 
Type of allo-HCT     
 MRD  26 24.5  
 MUD 59 55.6  
 haplo 9 8.4  
 MMUD 8-9/10 12 11  
Median EBMT risk score  3  (0-6) 
HCT-CI 1 52 49.5  
Disease risk index ( high + 
very high) 
38 35.8  
Median Pre-transplant 





performans status % 
90  (70-100) 
Note; MAC= Myeloablative conditioning regimen; RIC = Reduced intensity 
conditioning regimen; BM = Bone marrow; PBSC =Peripheral blood stem cell; 
MRD = Matched related donor; MUD =Matched unrelated donor; MMUD = 
Mismatch unrelated donor 
RESULTS 
According to the area under the curve (AUC) and 
with using receiver operating characteristic curve 
(ROC) analysis in many indexes like febrile 
neutropenia, bacterial infections, fungal infections, 
pneumonia, NRM and OS, the cutoff of ferritin was 
between 412.2 to 612 ng/mL for infectious complication 
and 737 ng/mL for NRM & OS (Table 2). 
 As the cutoffs the majority of infectious 
complications was near the 500 ng/mL value, which is 
in the literature considered moderate IO, we used it to 
analyze infectious complications, mucositis, febrile 
neutropenia, graft engraftment, hemorrhagic cystitis 
and number of RBC units transfused after allo-HCT. 
For NRM and OS analysis we used the higher cutoff 
737 ng/mL, which was determined statistically.  
Sixty-three (59.4%) patients (pts) had increased 
serum ferritin concentrations (500 ng/mL), and were 
classified as the high-ferritin group (HF), with a median 
of 1134.8 ng/mL (range, 511-4247). The rest of 
patients (n=43, 40.6%) were classified as LF group, 
and had serum ferritin concentrations (<500 ng/mL) 
with a median ferritin at 281.8 ng/mL (range, 12.1-
466.3).  
 Active infections within last month prior to HCT 
were observed only in HF group. There were sixteen 
cases; (8) pts with probable invasive pulmonary 
aspergillosis, (5) pts with bacterial infections, (2) pts 
with fever of unknown origin and (1) case hepatitis B, 
with a median ferritin level of 1080.5 ng/mL (606.1-
1875). Hence, fungal infections prevailed among total 
infections by the date of allo-HCT, and 25.4% of 
patients in HF group with increased ferritin levels, P= 
0.001; [OR], 0.73; 95% [CI], ( 0.62–0.86). 
Complications in the Early Period after Allogeneic-
HCT 
Mucositis 
Post-transplant mucositis was observed in eighty 
patients; 33 pts (52.3%) in HF and 21 (48%) in LF 
group had mucositis grade I-II, P =0.43; [OR], 1.15 ; 
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95% [CI], (0.53–2.5). 12 pts (19 %) in HF group versus 
14 (31.57%) in LF group had mucositis grade III-IV, P 
=0.08; [OR], 0.48 ; 95% [CI], (0.19–1.19). No statistical 
differences were observed between the two groups.  
Febrile Neutropenia 
Febrile neutropenia was observed in eighty cases; 
51(81%) in HF and 29 (67.4%) in LF (P > 0.05). 
Despite the lack of a statistically significant difference 
between the groups, we revealed a linear correlation 
between increasing ferritin level and numbers of febrile 
neutropenia episodes. The median for HF group was 
1.4 febrile episodes/ patient (rang, 0 to 6) vs 0.9 (0 to 
3) in LF patients, P = 0.02; [OR], 2.87; 95% [CI], (1.14–
7.21). In the same context, the number of patients who 
required granulocyte colony-stimulating factor (G-CSF) 
injections to boost hematopoiesis and to shorten 
neutropenic period was; 30 (47.3%) vs 9(21%) in the 
HF and LF groups, respectively, P =0.007; [OR], 3.4 ; 
95% [CI], (1.14–8.3).  
Bacterial Infections  
Although the percentage of patients exposed to 
bacterial infections was similar in both HF and LF 
groups (resp., 85.7, 84.2%), there was a distinct 
correlation between the increased pre-HCT ferritin and 
median number of infectious episodes/ patient, i.e., 
2.6(0 to 7) in HF group, and 2.0 (0 to 6) in LF sample, 
P = 0.009; [OR], 3; 95% [CI], (1.33–6.9). Incidence of 
blood-borne infections (septicemia) was more frequent 
in the HF group (n=23; 36.5%) vs (n=9; 21%) in LF 
patients, a statistical difference was absent, P = 0.06; 
[OR], 2.17; 95% [CI], (0.88-5.32). 
Pneumonia 
Increasing incidence of pneumonia was observed, 
regardless of its causes, in the first group (ferritin 500 
ng/mL) compared to the second group; 18 cases 
(28.6%) in HF vs 5 cases (11.6%) in LF, P =0.039, 
[OR], 3; 95%[CI], (1–8.9) . Mixed pathogens as causes 
of pneumonia were observed in a large proportion of 
patients (bacterial, fungal and viral pathogens); 55.5% 
and 60% in HF and LF groups, respectively. Isolated 
bacterial pneumonia was recorded only in HF group 
and formed 33.3% of causes of pneumonia. 
Fungal Infections  
In our cohort study, fungal infections were observed 
in 12 pts (19%) of HF group and 3 pts (7%) in LF 
group, with no statistically significant difference P 
=0.06, [OR], 3,1; 95%[CI], (0.8–11.8). 
Cytomegalovirus(CMV) Infections  
During the early period after allo-HCT, CMV 
reactivation was observed in 40 pts (37.7% of total), 
including 25(39.7%) in HF, and 15(34.8%) in LF group, 
without statistically significant difference P =0.38, [OR], 
1.22 ; 95%[CI], (0.54–2.74). There was no differences 
in the incidence of other viral infections like 
polyomavirus (BK, JC) between the two groups; 27% 
vs 21% in HF and LF, respectively, P =0.31, [OR], 1.39 
; 95%[CI], (0.55–3.50).  
Engraftment 
Median time of neutrophil (Neu  500 *109 ) and 
platelet recovery (Plt  20 *109 ) was, respectively, 22.3 
days (range, 13-43) and 18 days (10-38) in HF group, 
versus 20.3 days (11-36) and 16.6 days (11-36) in LF 
group. Neutrophil recovery was slower in the high 
ferritin group than in the low ferritin group, P =0.032, 
[OR], 0.2 ; 95%[CI], (0.04–0.97). That was independent 
of the stem cell dose; 5 (1.1-14.1)*10
6
 versus 4.7 (1.5-
10.1)*10
6
 in HF and LF. Intensity of conditioning 
regimens did not affect the engraftment rates in our 
cohort: MAC/ RIC; 25.3/ 74.6 % and 23.2/76.8 % in HF 
Table 2: Results of AUC & ROC Analysis to Determine the Cutoff Ferritin in Different Indexes 
Indexes AUC Sensitivity Specificity Cutoff Ferritin ng/mL 
Bacterial infection >2 episodes 0.599 0.717 0.567 608.55 
Febrile neutropenia >1 episode 0.600 0.879 0.438 412.20 
Septicemia 0.586 0.719 0.527 612.00 
Pneumonia 0.573 0.870 0.398 412.20 
Fungal infections 0.640 0.933 0.385 412.20 
VOD 0.664 0.500 0.941 1603.50 
NRM+OR 0.608 0.692 0.591 737.25 
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and LF groups, respectively. No statistically significant 
difference was observed in platelet recovery , P> 0.05. 
Hepatic Veno-Occlusive Disease (VOD)  
Only 4 cases were observed in total cohort; 3 in HF 
and 1 in LF group. The pre-HCT ferritin levels in these 
cases were as follows; 4247, 1631, 827.3, 112 ng/mL, 
and one case with primary myelofibrosis had severe 
VOD with multiorgan failure, and died on D7+ after 
transplantation.  
Acute and Chronic Graft-Versus-Host Disease 
(GvHD) 
Acute GvHD grade I-II and grade III-IV was 
diagnosed in 23 pts (37%) and 6 (9.5%) in HF vs 19 pts 
(44.2%) and 2 (4.6%) in LF, respectively. This 
difference was not statistically significant, P =0.46. The 
cumulative incidence of extensive chronic GvHD at 1 
year after transplantation was 16% in HF and 28% in 
LF without reaching statistically significant, P =0.1, 
[OR], 0.48 ; 95%[CI], (0.17–1.3). 
Blood Transfusion 
Number of RBC units transfused was counted for 
each patient within 100 days post-HCT, and the 
median number of RBC units/patient was 8.8 units 
(range, 0 to 36) and 3.8 units (0 to 27) in HF and LF 
groups respectively, P =0.002 ,[OR], 5.23 ; 95%[CI] , 
(1.65–16.55).  
The results of analysis regarding early and 
infectious complications are summarized in Figure 1 
One Year Outcomes of Allo-HCT 
With the estimated cutoff level  737 ng/mL the 
cumulative incidence of NRM within one year was 
higher in HF (25%) than in LF (10.3 %), P =0.024. The 
same pattern was observed for OS; 85% in LF vs 63% 
in HF, P = 0.002. On the contrary, there was no 
statistical differences in EFS and GRFS between HF 
and LF groups; 54% vs 66% (P =0.14) for EFS and 
40% vs 45% (P =0.4) for GRFS. However, on 
multivariate analysis we found that donor other than 
matched related (MRD) was the only factor that was 
associated with higher NRM and lower OS, P =0.044, 
[HR], 2.66; 95%[CI], (1.02–6.96) for NRM and , P 
=0.021 , [HR], 2.76 ; 95%[CI], (1.72–6.50) for OS. 
Ferritin was not a significant factor in multivariate for 
both NRM (P =0.28) and OS (P =0.55) (Table 3). 
The results of outcomes (NRM, OS, EFS and GRFS) 
analysis are summarized in Figure 2 (a,b,c,d) 
Correlation of the pre-HCT serum ferritin and C-
reactive protein (CRP) 
To exclude that the elevated pre-transplant ferritin 
was not due to IO, but the systemic inflammatory 
response (SIRS), we analyzed the association between 
serum ferritin and pre-transplant CRP levels. There 
was no statistically significant correlation between 
CRP> 5 and ferritin levels (P =0.055). So the observed 
differences in early complications based on ferritin level 
were not associated with presence of SIRS pre-HCT, 
but more likely due to IO. 
 
Figure 1: The percentage of early and infectious complications post allo-HCT in two groups of ferritin. We calculated recurrent 
febrile neutropenia >1 episode, recurrent bacterial infectious >2 episodes, need of stimulating factor (GCSF), incidence of 
pneumonia, multiple blood transfusion >9 units and the percentage of neutrophil engraftment in two ferritin groups. 
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Associations between pre allo-HCT ferritin levels 
and different risk indexes  
Surprisingly, we found statistically significant 
association between pre-transplant ferritin and all 
currently existing risk assessment indexes; EBMT 
score (P =0.0001), comorbidity index (HCT-CI) (P 
=0.003), Pre-transplant Assessment of Mortality Score 
(PAM) (P =0.007) and disease risk (DR)(P =0.037). 
Table 3: Univariate and Multivariate Analysis of Factors Effecting 1 Year Cumulative Non Relapse Mortality and 
Probability of overall Survival 
Factor Univariate, P-Value Multivariate, P-Value HR HR 95% CI 
Non-relapse mortality 
 Ferritin 737 0.024 0.28   
 Active disease at the time of HCT 0.011 0.27   
 Matched related vs other donor 0.002 0.044 2.66 (1.02-6.96) 
 CRP > 5 prior HCT 0.015 0.69   
Probability of overall survival 
 Ferritin 737 0.002 0.55   
 Active disease at the time of HCT <0.0001 0.13   
 Matched related vs other donor 0.004 0.019 2.76 (1.17-6.50) 
 CRP > 5 prior HCT 0.007 0.74   
 
 
Figure 2: Differences in 1 year outcomes between two ferritin groups with pre allo-HCT ferritin level cutoff >737 ng/mL (a) 
Cumulative incidence of 1 year non-relapse mortality (b) Probability of 1 year overall survival (c) Cumulative incidence of 1 year 
event free survival (d) Cumulative incidence of 1 year graft vs host disease -free relapse survival. 
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Despite, absence of a clear trend of increasing ferritin 
in risk groups from different scoring systems, there was 
a clear evidence of lower ferritin level in patients with 
lowest risk. Also there was a positive correlation 
between the ferritin level and PAM (r2=0.047, Figure 
3). 
DISCUSSION 
IO associates with increased susceptibility to 
different infections. Iron deprivation was found to be the 
key factor in the antimicrobial host defense. Several 
previous studies showed the impact of elevated serum 
ferritin on the increasing the incidence of bacterial, 
blood stream, fungal infections [25, 27, 28] and 
pneumonia [7] post allo-HCT. On the contrast, latest 
recent study, M Tanaka1 et al. [29], showed that the 
cumulative incidence of infection within 100 days after 
HCT, was not different between the two groups with 
(cutoff >1000 ng/mL). In our study we found that 
elevated ferritin more than 500 ng /mL pre allo-HCT 
associated with increasing number of febrile 
neutropenia episodes (P =0.02), increasing number of 
bacterial episodes, increased pneumonia incidence, 
predominantly the bacterial one. The observed results 
reflect a well-known negative effect of IO on anti-
infectious immunity [31-34]. In contrast to the published 
studies we didn’t find increased incidence of fungal 
infections, that may be related to aggressive center 
policy in pre-transplant fungal infection screening and 
secondary prophylaxis [35]. Also in accordance with 
published studies we found delayed engraftment and 
increased percentage of patients who required G-CSF 
stimulation in HF group [29]. 
 Also in this study we observed that patients who 
had high pre allo-HCT ferritin levels needed more blood 
transfusions than those who were in LF group. This 
may be explained in part by the presence of antibodies 
in heavily transfused patients [39] and by increasing 
incidence of febrile neutropenia and bacterial 
infections. In these inflammatory conditions the 
hepcidin is secreted as a defensive mechanism, which 
causes inhibition of iron realizing from its stores and 
thus prevents use iron in normal hematopoiesis and 
leads to slower recovery of erythroid lineage after 
HCT[40]. History of heavy blood transfusion 20 RBC 
units in last year before transplantation was recorded in 
14 pts, the median ferritin levels in these pts was 
1464.5 ng/mL (range, 650-4247). Only 3 patients were 
on chelation therapy with Exjade at the date of allo-
HCT and they discontinued it just prior conditioning 
regimen.  
 Interestingly, the statistical cutoffs for infectious 
complications and delay in the engraftment were lower 
(>500 ng/mL), than in published papers [3,4,8-10], 
which was usually 1000-3000 ng/mL. This may raise 
the question that some of the patients with moderate 
elevation of ferritin may have not the actual IO, but the 
systemic inflammatory response (SIRS) pre-transplant. 
Several studies postulated that moderately increased 
ferritin is associated with SIRS in the HCT and non-
HCT setting [30,41], but in our patient series we found 
no correlation between CRP and ferritin. Furthermore, 
CRP level was not statistically different in patients with 
ferritin above or below 500 ng/mL. So this may indicate 
that even moderate IO may be associated with 
increased incidence of complications in HCT recipients 
and may advocate use of chelation therapy before HCT 
 
Figure 3: The association between pre allo-HCT serum ferritin and risk assessment indexes; EBMT score, comorbidity index 
(HCT-CI), Pre-transplant Assessment of Mortality Score (PAM) and disease risk (DR). [N pts: Number of patients. Mean ±SD: 
Mean ferritin level ± Standard deviation] were calculated for every degrees of risk indexes. Disease risk index and PAM score 
were calculated only for malignant diseases (n=93). In the right liner correlation between pre allo-HCT ferritin and PAM score 
was observed (r2=0.047).  
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in patients with lower level of ferritin than 1000-2000 
ng/mL. This observation should be confirmed with 
large, adequately powered studies with MRI 
assessment of IO. 
 Many studies have shown an association between 
elevated serum ferritin before HCT (used as a 
surrogate measure of IO) and adverse overall survival 
[7-10,13,29] and NRM [7,8]. These studies used 
various cutoff levels (500-3000 ng/mL). On the other 
hand when pre-transplant IO was measured with MRI, 
there such differences were not observed in the two 
studies; Trottier et al, found no association between 
pre-transplant IO defined by R2-MRI measured LIC 
and OS, NRM, relapse rate or GvHD [14], similar 
results have been reported by Armand et al. [15]. In our 
study in multivariate analysis we found no association 
between pre-transplant ferritin, NRM and OS, although 
in univariate, the significant differences were observed. 
This may be due to relatively small group size and 
heterogeneity of indications for HCT and conditioning 
regimens. Partly, this is confirmed by the strong 
observed correlation between ferritin levels and all of 
the HCT risk assessment indexes, including EBMT, 
HCT-CI, DR, PAM. As all of them were developed 
using very large cohorts of patients, with larger study 
group, the observed differences in NRM and OS in HF 
and LF groups might have reached the statistical 
significance. 
 Furthermore, based on analysis of ferritin and 
transplant indexes, several interesting conclusions 
could be drawn. On the one hand, we found 
association between ferritin and NRM predictive 
indexes, like HCT-CI and PAM. These scoring systems 
include such parameters as liver, heart, kidney and 
lung dysfunction and infectious complications that at 
least partially may be associated with IO [36-38]. 
Indeed in our recurrent infections and liver dysfunctions 
were more common in HF group. So IO is one of the 
factors that increase the risk of HCT predicted by HCT-
CI and PAM. On the other hand, pre-transplant ferritin 
was associated with DR scores, which indicates that 
some proportion of the risk is not due to IO, but due to 
underlying disease itself, higher number of previous 
chemotherapy courses and poorer status at the time of 
HCT. 
In conclusion, as was previously published, we 
observed increased incidence of infectious complica- 
tions and adverse impact on engraftment, but also 
found that lower level of ferritin is associated with 
increased risk of these events. Also association of 
ferritin levels with major HCT mortality risk indexes, 
makes it simple and effective tool to predict the 
outcome of treatment. 
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